
Open wide!
Yesterday the U.S. Food and Drug Administration ruled that Invokana doubles the risk of foot and leg amputations in type 2 diabetics, compared to treatment with placebo. Invokana is an SGLT2 inhibitor called canagliflozin. There are several other drugs in that class, and we don’t know about the risk of amputations with them.
I don’t start any of my T2 diabetic patients on SGLT2 inhibitors. Instead of taking a pill to make your kidneys excrete carbohydrate, it’s smarter to reduce dietary carbohydrate consumption.
Steve Parker, M.D.